Skip to main content
. 2021 Sep 23;26(12):1006–e2129. doi: 10.1002/onco.13949

Serious Adverse Events

Name Grade Attribution
Anaphylaxis 3 Unrelated
Back pain 3 Unrelated
Gastrointestinal disorders ‐ Other, specify 3 Unrelated
Lung Infection 3 Unrelated
Neutrophil count decreased 2 Possible
Syncope 3 Unlikely
Urinary tract infection 3 Unrelated

After a median follow‐up of 22 months, adverse events for radium‐223 plus enzalutamide versus enzalutamide alone are reported.